ARTICLE | Clinical News
Masitinib: Phase II amended
November 11, 2013 8:00 AM UTC
AB Science amended an ongoing, double-blind, placebo-controlled, European Phase II trial of oral masitinib plus riluzole to designate it as a Phase III trial and increase enrollment to 210 patients fr...